A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Conditions:   Non-Hodgkin Lymphoma;   Follicular Lymphoma;   DLBCL;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma Intervention:   Drug: IGM-2323 Sponsor:   IGM Biosciences, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials